
Supplements and Featured Publications
- Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone
- Volume 27
- Issue 20
Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone - Participating Faculty
Faculty
Keith A. Betts, PhD
Vice President
Analysis Group
Los Angeles, CA
David Z. I. Cherney, MD, PhD
Professor of Medicine
University of Toronto
Toronto, ON
Yuxian Du, PhD
Manager
Research Strategy, Data Generation and
Observational Studies
Bayer Pharmaceuticals
Whippany, NJ
Elizabeth Faust, MBA, MPH
Manager
Analysis Group
New York, NY
Kerstin Folkerts, MSc
HEOR Senior Project Manager
HEOR Cardio, Renal, & Vascular Diseases
Bayer AG
Wuppertal, Germany
Linda F. Fried, MD, MPH
Professor of Medicine
Epidemiology, and Clinical & Translational Science
Associate Professor of Epidemiology
University of Pittsburgh
Pittsburgh, PA
Staff Physician, Renal Section
VA Pittsburgh Healthcare System
Pittsburgh, PA
Sheldon X. Kong, PhD
Executive Director
Research Strategy, Data Generation
and Observational Studies
Bayer Pharmaceuticals
Whippany, NJ
Csaba P. Kovesdy, MD
The Fred Hatch Professor of Medicine
Department of Medicine
Division of Nephrology
University of Tennessee Health Science Center
Memphis, TN
Pierre Levy, PhD
LEDa[LEGOS]
Université Paris-Dauphine
Paris, France
Paul Mernagh, MCom
Project leader, HEOR
Cardio, Renal, & Vascular Diseases
Bayer AG
Berlin, Germany
Aurélie Millier, PhD
Vice President
Health Economics and Outcomes Research
Creativ-Ceutical
Paris, France
Stephen Morris, PhD
RAND Professor of Health Services Research
Deputy Director
Primary Care Unit
Department of Public Health and Primary Care
University of Cambridge
Cambridge, UK
Natalia Petruski-Ivleva, PhD
Associate Director
Science
Aetion
Boston, MA
Michał T. Pochopien´, MSc
HEOR Principal
Creativ-Ceutical
Kraków, Poland
Prabir Roy-Chaudhury, MD, PhD
Director
University of North Carolina Kidney Center
Chapel Hill, NC
Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Niklas Schmedt, DrPH
Senior Outcomes Data Expert
Integrated Evidence Generation
& Business Innovation
Bayer AG
Berlin, Germany
Rakesh Singh, PhD
Director
Research Strategy, Data Generation
and Observational Studies
Bayer Pharmaceuticals
Whippany, NJ
Jinlin Song, PhD
Manager
Analysis Group
Los Angeles, CA
Sean D. Sullivan, PhD
Professor and Dean, School of Pharmacy
University of Washington
Seattle, WA
Priscilla Velentgas, PhD
Senior Principal
Real World Solutions
IQVIA
Cambridge, MA
Karen Yang, BA
Senior Analyst
Analysis Group
New York, NY
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Keith A. Betts, PhD
EMPLOYMENT
Employee of Analysis Group, a consulting
company that has provided paid consulting
services to Bayer Pharmaceuticals, which
funded the development and conduct of this
study and manuscript
David Z. I. Cherney, MD, PhD
CONSULTANCIES OR PAID ADVISORY BOARDS
Boehringer Ingelheim-Lilly, Merck,
AstraZeneca, Sanofi, Mitsubishi-Tanabe,
AbbVie, Janssen, Bayer Pharmaceuticals,
Prometic, Bristol Myers Squibb, Maze,
CSL-Berhring, and Novo-Nordisk
GRANTS RECEIVED
Boehringer Ingelheim-Lilly, Merck, Janssen,
Sanofi, AstraZeneca, and Novo-Nordisk
Yuxian Du, PhD
CONSULTANCIES OR PAID ADVISORY BOARDS
Received consulting fees from faculty emeritus
at the University of Washington
EMPLOYMENT
Employee of Bayer Pharmaceuticals,
sponsor of the study
STOCK OWNERSHIP
Bayer Pharmaceuticals, sponsor of the study
INSTITUTIONAL CONFLICTS OF INTEREST
Bayer Pharmaceuticals drug for chronic
kidney disease in patients with type 2 diabetes
approved in the United States
Elizabeth Faust, MBA, MPH
INSTITUTIONAL CONFLICTS OF INTEREST
Employee of Analysis Group, a consulting
company that has provided paid consulting
services to Bayer Pharmaceuticals, which
funded the development and conduct of this
study and manuscript
Kerstin Folkerts, MSc
EMPLOYMENT
Employee of Bayer AG, sponsor of the study
STOCK OWNERSHIP
Holding stocks and stock options from Bayer
AG, sponsor of the study
INSTITUTIONAL CONFLICTS OF INTEREST
Bayer Pharmaceuticals drug for chronic
kidney disease in patients with type 2 diabetes
approved in the United States
Linda F. Fried, MD, MPH
CONSULTANCIES OR PAID ADVISORY BOARDS
Consultant to Bayer Pharmaceuticals
Sheldon X. Kong, PhD
EMPLOYMENT
Employee of Bayer Pharmaceuticals
STOCK OWNERSHIP
Employee of Bayer Pharmaceuticals
with stock options
INSTITUTIONAL CONFLICTS OF INTEREST
Employee of Bayer Pharmaceuticals, which
produces Kerendia (finerenone) for the
treatment of chronic kidney disease associated
with type 2 diabetes
Csaba P. Kovesdy, MD
CONSULTANCIES OR PAID ADVISORY BOARDS
Consultant for AstraZeneca, Bayer
Pharmaceuticals
HONORARIA
Honoraria for consultant work from
AstraZeneca, Bayer Pharmaceuticals
Pierre Levy, PhD
HONORARIA
Honoraria received from Bayer
Pharmaceuticals for ad boards related to
the development of an economic model
for finerenone
Paul Mernagh, MCom
CONSULTANCIES OR PAID ADVISORY BOARDS
Previously an independent consultant
for Bayer Pharmaceuticals
EMPLOYMENT
Bayer AG employee
INSTITUTIONAL CONFLICTS OF INTEREST
Subject matter will be used to support market
launch of finerenone, which is produced by
Bayer Pharmaceuticals
Stephen Morris, PhD
HONORARIA
Honorarium from Bayer Pharmaceuticals for
participation in current manuscript
Prabir Roy-Chaudhury, MD, PhD
CONSULTANCIES OR PAID ADVISORY BOARDS
Consultant/Advisory Board for WL Gore,
Becton, Dickinson, and Company, Medtronic,
Humacyte, Cormedix, Akebia, Vifor-Relypsa,
Bayer Pharmaceuticals
Niklas Schmedt, DrPH
EMPLOYMENT
Employee of Bayer AG
INSTITUTIONAL CONFLICTS OF INTEREST
Bayer Pharmaceuticals drug for chronic
kidney disease in patients with type 2 diabetes
approved in the United States
Rakesh Singh, PhD
EMPLOYMENT
Employee of Bayer Pharmaceuticals,
sponsor of the study
STOCK OWNERSHIP
Bayer Pharmaceuticals, sponsor of the study
INSTITUTIONAL CONFLICTS OF INTEREST
Bayer Pharmaceuticals drug for chronic
kidney disease in patients with type 2 diabetes
approved in the United States
Jinlin Song, PhD
EMPLOYMENT
Employee of Analysis Group, a consulting
company that has provided paid consulting
services to Bayer Pharmaceuticals, which
funded the development and conduct of this
study and manuscript
Sean D. Sullivan, PhD
CONSULTANCIES OR PAID ADVISORY BOARDS
Bayer AG supported by time to assist with
model development
Priscilla Velentgas, PhD
EMPLOYMENT
Employee of IQVIA, which conducts research
for all of the world’s biopharma companies
Karen Yang, BA
INSTITUTIONAL CONFLICTS OF INTEREST
Employee of Analysis Group, a consulting
company that has provided paid consulting
services to Bayer Pharmaceuticals, which
funded the development and conduct of this
study and manuscript
Aurélie Millier, PhD; Natalia Petruski-Ivleva, PhD; and Michał T. Pochopien´, MSc,
report no relationships or financial interests with
any entity that would pose a conflict of interest
with the subject matter of this supplement.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.